Intellia Therapeutics, Inc. (NTLA) DCF Valuation
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
Intellia Therapeutics, Inc. (NTLA) Bundle
Looking to assess the intrinsic value of Intellia Therapeutics, Inc.? Our (NTLA) DCF Calculator integrates real-world data with extensive customization features, enabling you to refine your forecasts and make more informed investment choices.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 43.1 | 58.0 | 33.1 | 52.1 | 36.3 | 38.0 | 39.8 | 41.6 | 43.6 | 45.7 |
| Revenue Growth, % | 0 | 34.55 | -43.01 | 57.69 | -30.4 | 4.71 | 4.71 | 4.71 | 4.71 | 4.71 |
| EBITDA | -100.8 | -130.3 | -261.0 | -450.6 | -506.3 | -38.0 | -39.8 | -41.6 | -43.6 | -45.7 |
| EBITDA, % | -233.81 | -224.63 | -789.52 | -864.51 | -1395.77 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 5.6 | 6.3 | 6.9 | 7.6 | 9.0 | 6.4 | 6.7 | 7.0 | 7.3 | 7.7 |
| Depreciation, % | 12.96 | 10.88 | 20.85 | 14.53 | 24.74 | 16.79 | 16.79 | 16.79 | 16.79 | 16.79 |
| EBIT | -106.4 | -136.6 | -267.9 | -458.2 | -515.3 | -38.0 | -39.8 | -41.6 | -43.6 | -45.7 |
| EBIT, % | -246.78 | -235.51 | -810.37 | -879.04 | -1420.51 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 279.7 | 597.4 | 1,086.0 | 1,262.0 | 912.2 | 38.0 | 39.8 | 41.6 | 43.6 | 45.7 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 4.6 | 2.1 | 2.0 | 3.8 | 36.5 | 9.7 | 10.2 | 10.6 | 11.1 | 11.7 |
| Account Receivables, % | 10.72 | 3.67 | 6.14 | 7.23 | 100.5 | 25.55 | 25.55 | 25.55 | 25.55 | 25.55 |
| Inventories | .0 | -19.1 | -337.4 | -69.3 | .0 | -17.7 | -18.5 | -19.4 | -20.3 | -21.3 |
| Inventories, % | 0.000002320024 | -33.01 | -1020.67 | -133.03 | 0 | -46.6 | -46.6 | -46.6 | -46.6 | -46.6 |
| Accounts Payable | 3.9 | 10.5 | 9.7 | 5.2 | 7.5 | 6.6 | 6.9 | 7.2 | 7.6 | 7.9 |
| Accounts Payable, % | 9.14 | 18.04 | 29.2 | 9.89 | 20.54 | 17.36 | 17.36 | 17.36 | 17.36 | 17.36 |
| Capital Expenditure | -6.8 | -3.6 | -12.8 | -58.4 | -14.0 | -15.1 | -15.8 | -16.6 | -17.4 | -18.2 |
| Capital Expenditure, % | -15.76 | -6.18 | -38.59 | -112.03 | -38.55 | -39.82 | -39.82 | -39.82 | -39.82 | -39.82 |
| Tax Rate, % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBITAT | -99.1 | -127.8 | -259.7 | -473.6 | -515.3 | -36.7 | -38.5 | -40.3 | -42.2 | -44.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -100.9 | -96.9 | 52.0 | -798.7 | -620.0 | -1.9 | -46.9 | -49.1 | -51.5 | -53.9 |
| WACC, % | 12.11 | 12.11 | 12.13 | 12.14 | 12.14 | 12.13 | 12.13 | 12.13 | 12.13 | 12.13 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -136.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -55 | |||||||||
| Terminal Value | -543 | |||||||||
| Present Terminal Value | -306 | |||||||||
| Enterprise Value | -443 | |||||||||
| Net Debt | -111 | |||||||||
| Equity Value | -332 | |||||||||
| Diluted Shares Outstanding, MM | 89 | |||||||||
| Equity Value Per Share | -3.74 |
What You Will Get
- Pre-Filled Financial Model: Intellia Therapeutics’ actual data allows for accurate DCF valuation.
- Full Forecast Control: Modify revenue growth, profit margins, discount rates, and other essential metrics.
- Instant Calculations: Real-time updates provide immediate feedback as adjustments are made.
- Investor-Ready Template: A polished Excel file crafted for high-quality valuation presentations.
- Customizable and Reusable: Designed for adaptability, enabling repeated use for in-depth forecasts.
Key Features
- Comprehensive DCF Analysis Tool: Offers in-depth unlevered and levered DCF valuation frameworks tailored for Intellia Therapeutics, Inc. (NTLA).
- WACC Estimator: Pre-configured Weighted Average Cost of Capital sheet with adjustable parameters specific to the biotech sector.
- Customizable Forecast Variables: Adjust growth projections, R&D expenses, and discount rates to align with market conditions.
- Integrated Financial Metrics: Evaluate profitability, leverage, and operational efficiency ratios pertinent to Intellia Therapeutics, Inc. (NTLA).
- Interactive Dashboard and Graphs: Visual representations that encapsulate essential valuation indicators for straightforward interpretation.
How It Works
- Step 1: Download the prebuilt Excel template featuring Intellia Therapeutics’ data.
- Step 2: Review the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Immediately see recalculated results, including Intellia Therapeutics’ intrinsic value.
- Step 5: Utilize the outputs to make informed investment decisions or create reports.
Why Choose Intellia Therapeutics, Inc. (NTLA)?
- Innovative Solutions: Leverage cutting-edge gene editing technologies that are at the forefront of medicine.
- Commitment to Safety: Rigorous testing and compliance ensure the highest standards in patient care.
- Expert Team: Benefit from a team of industry leaders dedicated to advancing therapeutic options.
- Robust Pipeline: A diverse range of therapies in development targeting various genetic diseases.
- Proven Track Record: Backed by successful collaborations and partnerships in the biotech space.
Who Should Use Intellia Therapeutics, Inc. (NTLA)?
- Investors: Gain insights into cutting-edge gene editing technologies to make informed investment choices.
- Biotech Analysts: Streamline your analysis with comprehensive data on Intellia's pipeline and market potential.
- Healthcare Consultants: Efficiently modify reports or presentations to highlight Intellia's innovations for clients.
- Life Sciences Enthusiasts: Enhance your knowledge of gene therapies and their implications through real-world case studies.
- Educators and Students: Utilize it as a valuable resource for understanding biopharmaceutical advancements in academic settings.
What the Template Contains
- Comprehensive DCF Model: Editable template featuring detailed valuation calculations tailored for Intellia Therapeutics, Inc. (NTLA).
- Real-World Data: Intellia's historical and projected financials preloaded for in-depth analysis.
- Customizable Parameters: Modify WACC, growth rates, and tax assumptions to explore various scenarios.
- Financial Statements: Complete annual and quarterly breakdowns providing deeper insights into the company's performance.
- Key Ratios: Integrated analysis for profitability, efficiency, and leverage metrics specific to Intellia Therapeutics, Inc. (NTLA).
- Dashboard with Visual Outputs: Charts and tables designed for clear, actionable insights and results.